Stoke Therapeutics Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Stoke Therapeutics yıllık ortalama 13.1% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 33.8% annual. Gelirler yılda ortalama 71.8% oranında büyüyor .
Anahtar bilgiler
13.06%
Kazanç büyüme oranı
20.53%
EPS büyüme oranı
| Biotechs Sektör Büyümesi | 17.04% |
| Gelir büyüme oranı | 71.80% |
| Özkaynak getirisi | -42.99% |
| Net Marj | -529.20% |
| Son Kazanç Güncellemesi | 31 Mar 2026 |
Yakın geçmiş performans güncellemeleri
Recent updates
Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Are Pretty Bullish On The Stock After Recent Results
As you might know, Stoke Therapeutics, Inc. ( NASDAQ:STOK ) just kicked off its latest quarterly results with some very...
Phase III Trial And Payer Risks Will Shape Dravet Treatment Prospects
Catalysts About Stoke Therapeutics Stoke Therapeutics is a biotechnology company focused on RNA-based medicines, including zorevunersen for Dravet syndrome. What are the underlying business or industry changes driving this perspective?Stoke Therapeutics: Zorevunersen Has Disease-Modifying Potential In Dravet Syndrome
Summary I initiate Stoke Therapeutics with a Buy rating, driven by late-stage progress for zorevunersen in SCN1A Dravet Syndrome. STOK's phase 3 EMPEROR trial for zorevunersen targets mid-2027 data and a rolling NDA submission in the first half of 2027. Three-year open-label data show durable seizure reduction and functional improvement, supporting disease-modifying potential for zorevunersen. STOK's $390.9M cash position, Biogen partnership, and low burn rate provide runway into mid-2028, mitigating near-term financing risk. Read the full article on Seeking AlphaNewsflash: Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Have Been Trimming Their Revenue Forecasts
The analysts covering Stoke Therapeutics, Inc. ( NASDAQ:STOK ) delivered a dose of negativity to shareholders today, by...Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 36% But Its Business Still Trails The Industry
Despite an already strong run, Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shares have been powering on, with a gain of...Stoke Therapeutics, Inc. (NASDAQ:STOK) Held Back By Insufficient Growth Even After Shares Climb 39%
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shares have continued their recent momentum with a 39% gain in the last month...Improved Revenues Required Before Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock's 49% Jump Looks Justified
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shares have continued their recent momentum with a 49% gain in the last month...Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Could Be 25% Above Their Intrinsic Value Estimate
NasdaqGS:STOK 1 Year Share Price vs Fair Value Explore Stoke Therapeutics's Fair Values from the Community and select...Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 28% But Its Business Still Trails The Industry
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shareholders would be excited to see that the share price has had a great...Analysts Are More Bearish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Than They Used To Be
Market forces rained on the parade of Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shareholders today, when the analysts...Stoke Therapeutics, Inc.'s (NASDAQ:STOK) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
To the annoyance of some shareholders, Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shares are down a considerable 27% in...We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer
Summary Stoke Therapeutics' RNA-based treatments for severe neurological and ophthalmic disorders, particularly zorevunersen for Dravet syndrome, show potential for long-term value beyond a single drug. Financials reveal high R&D spending and cash burn, but revenue growth from Acadia Pharmaceuticals collaboration suggests early monetization and potential non-dilutive funding. The Phase 3 EMPEROR study for zorevunersen is critical, with regulatory alignment and promising early data, but execution and long-term safety monitoring remain challenges. Stoke's broader pipeline, including treatments for SYNGAP1-related disorders, Rett syndrome, and Autosomal Dominant Optic Atrophy, could expand its market potential if RNA modulation proves broadly effective. Read the full article on Seeking AlphaEarnings Update: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Reported And Analysts Are Trimming Their Forecasts
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) just released its third-quarter report and things are looking bullish. Results...Industry Analysts Just Made A Huge Upgrade To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenue Forecasts
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shareholders will have a reason to smile today, with the analysts making...Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome
Summary STOK's zorevunersen shows strong efficacy in reducing seizures but has safety concerns, particularly elevated CSF protein levels, needing further monitoring. Dravet Syndrome market potential is significant, with 35,000 patients in key regions and existing treatments costing up to $96,000 annually. STOK has a solid cash runway for 7-8 quarters, with a Phase 3 trial expected to start soon, aiming for topline data by mid-2026. Despite recent stock gains, I may consider investing when Phase 3 trial enrollment is announced, given the promising genetic approach to Dravet Syndrome. Read the full article on Seeking AlphaWe're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome
Summary Stoke Therapeutics' TANGO platform enhances RNA output to compensate for gene mutations causing severe genetic diseases. STOK primarily focuses on developing treatments for Dravet syndrome and autosomal dominant optic atrophy (ADOA). STK-001, a Phase 1/2 candidate for Dravet syndrome, shows promising clinical results with seizure reduction and cognitive improvements. Collaborations with ACAD involve significant milestones and potential royalty payments, enhancing its financial outlook. STOK's financials are strong, with a healthy cash runway and potential for significant royalty revenues, making it a promising investment. Read the full article on Seeking AlphaGelir ve Gider Dağılımı
Stoke Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 31 Mar 26 | 32 | -170 | 72 | 145 |
| 31 Dec 25 | 184 | -7 | 67 | 138 |
| 30 Sep 25 | 206 | 41 | 59 | 120 |
| 30 Jun 25 | 200 | 52 | 55 | 104 |
| 31 Mar 25 | 191 | 50 | 53 | 99 |
| 31 Dec 24 | 37 | -89 | 49 | 89 |
| 30 Sep 24 | 17 | -105 | 47 | 87 |
| 30 Jun 24 | 15 | -104 | 44 | 86 |
| 31 Mar 24 | 8 | -109 | 41 | 85 |
| 31 Dec 23 | 9 | -105 | 41 | 82 |
| 30 Sep 23 | 9 | -103 | 40 | 82 |
| 30 Jun 23 | 9 | -105 | 40 | 81 |
| 31 Mar 23 | 15 | -99 | 40 | 79 |
| 31 Dec 22 | 12 | -101 | 39 | 78 |
| 30 Sep 22 | 9 | -100 | 38 | 73 |
| 30 Jun 22 | 6 | -96 | 37 | 67 |
| 31 Mar 22 | 3 | -94 | 34 | 63 |
| 31 Dec 21 | 0 | -86 | 32 | 54 |
| 30 Sep 21 | 0 | -76 | 29 | 47 |
| 30 Jun 21 | 0 | -67 | 26 | 41 |
| 31 Mar 21 | 0 | -58 | 23 | 35 |
| 31 Dec 20 | 0 | -52 | 21 | 32 |
| 30 Sep 20 | 0 | -48 | 19 | 30 |
| 30 Jun 20 | 0 | -43 | 17 | 29 |
| 31 Mar 20 | 0 | -38 | 14 | 27 |
| 31 Dec 19 | 0 | -32 | 12 | 24 |
| 30 Sep 19 | 0 | -26 | 9 | 20 |
| 30 Jun 19 | 0 | -21 | 7 | 15 |
| 31 Mar 19 | 0 | -16 | 6 | 11 |
| 31 Dec 18 | 0 | -13 | 4 | 8 |
Kaliteli Kazançlar: STOK şu anda kârlı değil.
Büyüyen Kar Marjı: STOK şu anda kârlı değil.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: STOK kârlı değildir, ancak son 5 yılda zararlarını yılda 13.1% oranında azaltmıştır.
Büyüme Hızlandırma: STOK 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil
Kazançlar vs. Sektör: STOK kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 43% ) karşılaştırılması zorlaşıyor.
Özkaynak Getirisi
Yüksek ROE: STOK hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -42.99% ) sahiptir.
Varlık Getirisi
Kullanılan Sermaye Getirisi
Geçmişte güçlü performans gösteren şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/24 14:00 |
| Gün Sonu Hisse Fiyatı | 2026/05/22 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Stoke Therapeutics, Inc. 21 Bu analistlerden 11, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Gregory Harrison | BofA Global Research |
| Thomas Shrader | BTIG |
| Michelle Gilson | Canaccord Genuity |